Tokyo, September 18, 2020: Eisai Co., Ltd. has announced that the latest results from the cohort targeting patients with HER2-negative…
NEW DELHI, NOVEMBER-07-2019: The US Food and Drug Administration (FDA) has approved Sandoz’ biosimilar Ziextenzo (pegfilgrastim-bmez). The biosimilar pegfilgrastim has been…
Pelgraz, – a pegylated G-CSF Biosimilar, is the latest addition to its established portfolio of over 30 oncology treatments across…